Scilex Holding Company secures up to $100M non-recourse loan
Scilex Holding Company, through its wholly owned subsidiary SCLX Stock Acquisition JV LLC, entered into a non-recourse loan agreement for up to $100 million, secured by its common stock.
Rhea-AI Filing Summary
Scilex Holding Company, through its wholly owned subsidiary SCLX Stock Acquisition JV LLC, entered into a non-recourse loan agreement for up to $100 million, secured by its common stock. The lender, The St. James Bank & Trust Company Ltd., may fund the loan in multiple tranches at its sole discretion. The loan bears interest at the 12‑month Secured Overnight Financing Rate, and SCLX JV must also pay a 0.25% fee on the principal amount of each tranche.
The loan matures on the eighth anniversary of the closing date of the first tranche and may be extended by up to 12 months at SCLX JV’s request. As collateral, SCLX JV pledges shares of Scilex common stock equal to 70% of the aggregate principal amount of the loan, held in a securities account with the lender. Default triggers include a drop of more than 20% in the closing price of the pledged shares that is not cured within three days with additional collateral or cash, a more than 20% decline in three-day average trading volume versus the prior 30‑day average, or delisting of the shares. Upon an uncured default, the interest rate increases by 5.0% per year and the lender may foreclose on or dispose of the pledged shares.
Positive
- None.
Negative
- None.
Insights
Scilex secures up to $100 million non-recourse funding backed by its stock.
The company, via SCLX Stock Acquisition JV LLC, has arranged a non-recourse loan facility of up to $100 million with The St. James Bank & Trust Company Ltd. The lender controls the timing and size of each tranche, the loan accrues interest at the 12‑month Secured Overnight Financing Rate, and each tranche carries an additional fee of 0.25% of its principal amount.
Collateral consists of Scilex common shares pledged in an amount equal to 70% of the aggregate loan principal, held in a securities account with the lender. The loan’s term runs to the eighth anniversary of the first tranche closing, with an option to extend by up to 12 months. Because the loan is non-recourse, the lender’s primary remedy is against the pledged shares rather than other assets.
Default provisions are tightly linked to equity performance and market conditions. An uncured drop of more than 20% in the closing price of the pledged shares, a more than 20% decline in three-day average trading volume versus the prior 30‑day average, or a delisting can trigger default. If that occurs and is not cured within the specified period, the interest rate steps up by an additional 5.0% per annum and the lender may foreclose on or dispose of the pledged shares, so the economic impact will depend on future share price and trading dynamics.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Scilex Holding Company (SCLX) disclose in this 8-K?
How large is the new loan facility obtained by Scilex (SCLX)?
What secures the non-recourse loan for Scilex (SCLX)?
When does the Scilex non-recourse loan mature?
What interest and fees apply to the Scilex loan?
What events can trigger a default under Scilex’s loan agreement?
What happens if there is an uncured default on the Scilex loan?
AI-generated analysis. How Rhea-AI works. Not financial advice.